Tabrecta (capmatinib) vs Retsevmo (selpercatinib)

Tabrecta (capmatinib) is a targeted therapy approved for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has a specific mutation known as MET exon 14 skipping. Retsevmo (selpercatinib), on the other hand, is designed to treat certain types of thyroid cancer and NSCLC that are RET fusion-positive. When deciding between these two medications, it is crucial to have a molecular diagnosis to determine if the cancer harbors the specific genetic alterations (MET exon 14 skipping for Tabrecta or RET fusion for Retsevmo) that each drug is designed to target, as their effectiveness is contingent upon the presence of these mutations.

Difference between Tabrecta and Retsevmo

Metric	Tabrecta (capmatinib)	Retsevmo (selpercatinib)
Generic name	Capmatinib	Selpercatinib
Indications	Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations	Advanced or metastatic RET-driven lung and thyroid cancers
Mechanism of action	MET kinase inhibitor	RET kinase inhibitor
Brand names	Tabrecta	Retsevmo
Administrative route	Oral	Oral
Side effects	Peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite	Increased ALT/AST, increased blood glucose, decreased white blood cell count, decreased albumin, decreased calcium, dry mouth, diarrhea, increased creatinine, increased alkaline phosphatase, hypertension, fatigue, lymphopenia, anemia, increased uric acid, fever, edema, and constipation
Contraindications	None known	None known
Drug class	Tyrosine kinase inhibitor	Tyrosine kinase inhibitor
Manufacturer	Novartis Pharmaceuticals Corporation	Eli Lilly and Company

Efficacy

Introduction to Tabrecta (capmatinib) in Lung Cancer Treatment

Tabrecta (capmatinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that harbors specific mutations. These mutations are in the MET gene, known as MET exon 14 skipping mutations. Tabrecta is a MET inhibitor that targets the abnormal MET protein caused by these mutations, which can lead to cancer growth. The approval of Tabrecta was based on the efficacy results from the GEOMETRY mono-1 trial, which showed a notable response rate in patients with MET exon 14 skipping-mutated NSCLC.

Efficacy of Tabrecta in Clinical Trials

In the pivotal trial, patients treated with Tabrecta demonstrated a significant response, with a reported overall response rate (ORR) of 68% in newly diagnosed patients and 41% in previously treated patients. The duration of response (DOR) also supported the drug's efficacy, with many patients experiencing a sustained response. These results indicate that Tabrecta is an effective treatment option for patients with this specific genetic alteration in their lung cancer.

Introduction to Retsevmo (selpercatinib) in Lung Cancer Treatment

Retsevmo (selpercatinib) is another targeted therapy that has been granted accelerated approval by the FDA for the treatment of certain types of NSCLC. Specifically, Retsevmo is indicated for patients with NSCLC that have RET (rearranged during transfection) gene alterations. Selpercatinib is a RET inhibitor that blocks the activity of the RET protein, which can drive tumor growth in cancers that have RET gene changes. The efficacy of Retsevmo was evaluated in a multi-cohort clinical trial (LIBRETTO-001) that included patients with RET fusion-positive NSCLC.

Efficacy of Retsevmo in Clinical Trials

The clinical trial data for Retsevmo showed impressive efficacy outcomes. The ORR for previously untreated patients was approximately 85%, and for those who had received prior treatment, the ORR was around 64%. The DOR was also noteworthy, with many patients maintaining their response over time. These results demonstrate that Retsevmo is a highly effective treatment option for NSCLC patients with RET gene alterations, offering a new hope for this subset of lung cancer patients.

Regulatory Agency Approvals

Tabrecta

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Retsevmo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Tabrecta or Retsevmo today

If Tabrecta or Retsevmo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tabrecta

Buy Retsevmo

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: